Last reviewed · How we verify
A Therapeutic Trial of Intralesional Bevacizumab in Patients With Non-pedunculated Keloids
Keloid is chronic skin conditions that results in formation of tumor like growths on the skin. Despite its benign nature, keloid can cause severe aesthetic and, in some cases, functional problem which negatively impacts person's quality of life. Keloids do not regress on their own and results of most available treatments such as surgery, injecting keloids with steroids, chemotherapy injections, or even radiation therapy, have mostly proven disappointing. Some laboratory studies have shown that there is excessive amount of a protein called "vascular endothelial growth factor (VEGF)" in keloid tissue. This may play role in the formation and evolution of keloid. Bevacizumab is a drug that works by targeting vascular endothelial growth factor (VEGF) which helps new blood vessels form. Without new blood vessels, the growth of the keloid may be slowed Based on presence of excess amount of VEGF in keloid tissue, we hypothesize that bevacizumab will be effective in treatment of keloids. This exploratory clinical trial is to confirm or reject this hypothesis.
Details
| Lead sponsor | Tirgan, Michael H., M.D. |
|---|---|
| Phase | Phase 2 |
| Status | TERMINATED |
| Enrolment | 2 |
| Start date | 2012-02 |
| Completion | 2012-11 |
Conditions
- Keloid
Interventions
- bevacizumab
Primary outcomes
- The primary endpoint of this trial is to demonstrate the response rate of non-pedunculated keloids to bevacizumab. — 1 year
The primary objective of this trial is to demonstrate the efficacy of bevacizumab in patients with non-pedunculated keloids. Patients will be followed for one year since their last bevacizumab to assess post-therapy duration of response as well as the rate of recurrence.
Countries
United States